prompt1 : extract information from  breast pathology report. List the histological classification, i.e. type of cancer or DCIS, subtype, description of any necrosis, any mention of tumor infiltrating lymphocytes,  histological grade, nuclear grade,  lymphovascular invasion, calcification, receptor status, IHC and any other ancillary testing results.  List out and expand the main points.
prompt2 : The report is - ; Final Diagnosis. Breast, right, simple mastectomy: Multiple (2) nodules of invasive mammary carcinoma are. identified. Infiltrating lobular carcinoma, Nottingham grade I (of III) [tubules 3/3, nuclei 1/3,. mitoses 1/3; Nottingham score 5/9] is identified forming a mass (1.1 x 0.9 x 0.8 cm) located in. the upper outer quadrant of the breast [AJCC pTlc]. This cancer shows HER2/neu protein. overexpression (scored as 2+; see comment below) and has metastasized to right axillary sentinel. lymph node No. 1D as a roughly 1.1 mm keratin positive collection of tumor cells barely visible. by routine H&E morphology (see comment regarding right axillary sentinel lymph node excision. below). Infiltrating ductal carcinoma, Nottingham grade I (of III) [tubules /3, nuclei /3, mitoses /3;. Nottingham score /9] is identified forming a second lesion (1.7 x 1.5 x 0.9 cm) in the upper outer. quadrant located 0.6 cm inferior and medial to the first lobular carcinoma mass [AJCC pT1c]. This tumor also shows HER2/neu protein overexpression (scored as 2+; see comment below). However, there is no morphologic evidence of metastasis by this second lesion into any of the. sentinel lymph nodes. Extensive ductal carcinoma in situ, intermediate nuclear grade, is present within and outside the. invasive component with a separate nodule in the central/deep breast, 1.2 x 1.2 x 0.6 cm, located. 1.4 cm medial to the infiltrating ductal carcinoma. Angiolymphatic invasion is not seen. The. non-neoplastic breast parenchyma shows proliferative fibrocystic changes. Biopsy site changes. are present. The tumor does not involve the nipple, overlying skin, or underlying chest wall. All. surgical resection margins, including the deep margin, are negative for tumor (minimum tumor. free margin, 0.4 cm, anterior/superior margin). Lymph nodes, right axillary sentinel, excision: A single (of 12) right axillary sentinel lymph. node is positive for metastatic carcinoma [AJCC pN1 mi (sn)]. This positive sentinel node is. designated No. 1D (tissue block A4) and is characterized by a roughly 1.1 mm collection of. keratin positive tumor cells without much in the way of H&E morphologic correlation. As noted. above, this microscopic focus of cancer has lobular features. The remaining 11 right axillary. sentinel lymph nodes are negative for metastatic cancer (verified by keratin immunostaining). Blue dye is identified in right axillary sentinel lymph nodes No. 1A, No. 2A, No. 3A, No. 3B, and. No. 4. Blue dye is not identified in right axillary sentinel lymph nodes No. 1B, No. 1C, No. 1D,. No. 2B, No. 2C, No. 2D, or No. 3C. HER2/neu protein overexpression is weakly positive, score of 2+, according to the interpretation. guidelines in the FDA-approved HercepTest This degree of overexpression is seen in both tumor. nodules (using tissue blocks B2 and B4). Fluorescence in situ hybridization (FISH) for. HER2/neu amplification will be performed and reported in an addendum. HER2 protein immunohistochemical (IHC) test results are only valid for non-decalcified paraffin. embedded specimens fixed in neutral buffered formalin or Bouin's fixatives. Testing is. performed using commercially available kit/reagents employing a polyclonal antibody and a. polymer-based detection system. ADDENDA: No amplification for HER2/neu is demonstrated by fluorescence in situ hybridization (FISH,. performed in Laboratory Genetics) (blocks B2 and B4) according to the interpretation guidelines. in the FDA approved PathVysion Her2 DNA Probe Kit.

expanded version (tokens=1315) : 
 Histological classification: The breast pathology report reveals that there are multiple nodules of invasive mammary carcinoma identified in the right breast. There are two types of invasive carcinoma - infiltrating lobular carcinoma, Nottingham grade I, and infiltrating ductal carcinoma, Nottingham grade I. In addition, extensive ductal carcinoma in situ of intermediate nuclear grade and a separate nodule in the central/deep breast are present.

Subtype: The first lesion is classified as infiltrating lobular carcinoma while the second lesion is classified as infiltrating ductal carcinoma. 

Necrosis: No necrosis is mentioned in the report.

Tumor infiltrating lymphocytes: The report does not mention any tumor infiltrating lymphocytes.

Histological grade: The infiltrating lobular carcinoma is Nottingham grade I (of III) with a tubules 3/3, nuclei 1/3, and mitoses 1/3; Nottingham score 5/9, while the infiltrating ductal carcinoma is also Nottingham grade I (of III) with tubules /3, nuclei /3, mitoses /3; Nottingham score /9.

Nuclear grade: The report provides a nuclear grade for the infiltrating lobular carcinoma, which is 1 out of 3.

Lymphovascular invasion: Angiolymphatic invasion is not seen in the report.

Calcification: The report does not mention any calcifications.

Receptor status: According to the report, HER2/neu protein overexpression is

prompt : Please generate a succinct report in 75 words from the above information. Exclude any filler words or sentences. If something is not mentioned or specified, exclude it from the report. Low verbosity.

final output (tokens=1472) : 
 The pathology report for a  simple mastectomy of the right breast revealed multiple nodules of invasive mammary carcinoma. The first nodule was an infiltrating lobular carcinoma, Nottingham grade I, and the second was an infiltrating ductal carcinoma, Nottingham grade I. The tumor has HER2/neu protein overexpression with no morphologic evidence of metastasis. Extensive ductal carcinoma in situ of intermediate nuclear grade is present. Fluorescence in situ hybridization (FISH) for HER2/neu amplification performed is negative.

